Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.
Chris Spivey, editorial director, speaks with Vibha Jawa, executive director at Bristol Myers Squibb, on foreign epitopes recognition in what should be fully human antibody therapies. Can HLA genotyping show which binding targets will be most effective per individual patient, or per T cell response predictor in terms of a reverse translation in the clinic? A tangent from our upcoming conversation focused on High Titer Vector Producing Cells.
